A Double Masked Minimization in Ophthalmology Study
Phase II study conducted with a dose-escalation minimization A phase II ophthalmology study was conducted with a dose-escalation minimization to…
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras vel sagittis libero, a lacinia nisi. Interdum et malesuada fames ac ante ipsum primis in faucibus. Donec nec nisl turpis. Pellentesque pretium pellentesque maximus. Nam efficitur massa justo, eget laoreet odio congue convallis. Proin sagittis mauris sit amet justo cursus, sit amet porta eros eleifend. Nullam felis tortor, pharetra a consequat eget, luctus non massa. Cras sed efficitur felis, sollicitudin gravida eros. Mauris congue efficitur tempor.
Renseigner une description via Articles > Categories > Case Studies > Champ 'Description' pour remplacer ce Lorem ipsum.
Phase II study conducted with a dose-escalation minimization A phase II ophthalmology study was conducted with a dose-escalation minimization to…
Biostatistical Expertise For Developing New Biomarkers And Diagnostic Tests IDDI has a long-term collaboration with a Sponsor to provide biostatistical…
A Bayesian Study Design For Seamless Transition Between Phase II And Phase III Data collected by a sponsor suggested a…
A Flexible Study Design with Randomization to Placebo The maximum tolerated dose of a new drug, supposed to alleviate some…
New prognostic biomarkers for breast cancer: A range of biological markers were analyzed by polymerase chain reaction and immunohistochemistry in…
In this meta-analysis, tumor responses and survival were analyzed combining the data from the different trials using patient individual data. The…
Data Safety Monitoring Formal data safety monitoring, often performed by independent committees of physicians, biostatisticians and ethicists, has become common…
A 70-genetic signature was shown in a single institution to have prognostic value in patients with node-negative breast cancer. The…
Adverse Events coded by IDDI Medical Coding System Two pivotal trials were conducted (one in the US, one in Europe)…
A new ophthalmic drug was going to enter a phase II dose-ranging trial in order to determine the dose to…